What Castilium Treats: Main Uses and Benefits

Castilium (Clobazam) is commonly used to help with symptomatic relief and stabilization across conditions characterized by periods of heightened symptoms related to excessive neurological activity and tension.

This medication is relevant in clinical settings that involve acute or unstable symptom patterns. Its use is relevant in conditions involving episodic or fluctuating manifestations, such as certain epilepsy syndromes (like Lennox-Gastaut Syndrome) and conditions presenting with significant discomfort or tension.

It may be part of symptomatic management for both seizure-related neurological instability and persistent emotional tension. It is relevant for easing symptoms related to heightened physiological activity, such as symptoms of increased neurological or muscular activity.

“This medication assists with maintaining a sense of stability and contributes to improved comfort during periods of heightened symptoms.”

---

Quick Fact: Relief for Symptomatic Burden

The medication contributes to maintaining a sense of stability when symptoms are more noticeable. It provides supportive relief that helps patients cope more steadily with difficult episodes and may contribute to easing the overall symptom load associated with recurrent manifestations.

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Castilium?

Population eligibility for Castilium (Clobazam) is defined by official regulatory documentation and is strictly based on age, pre-existing conditions, and physiological status.

Absolute Contraindications

Use is contraindicated in several specific patient groups. These include individuals with known Hypersensitivity to the formulation, Myasthenia Gravis, Severe Respiratory Insufficiency, or Sleep Apnoea Syndrome. The medicine is also prohibited for patients with Severe Hepatic Insufficiencies and those with a history of Drug or Alcohol Dependence/Abuse.

Age and Condition Restrictions

Use is established for patients 2 years of age and older for the approved indication. However, safety and efficacy are not established for children younger than 2 years of age. Older adults (≥65 years) require a lower initial dose and slower dose escalation. Conditional use applies to patients with Mild to Moderate Hepatic Impairment, who require a lower starting dose and slower titration. Use is not recommended for patients with Severe Renal Impairment.

Reproductive Status

Regarding pregnancy, use is contraindicated in the first trimester in some regions. The medicine is also contraindicated for breastfeeding women due to its excretion into human milk.

Castilium interactions primarily involve the central nervous system (CNS) and the Cytochrome P450 enzyme system.

CNS Depressant Interactions

The most critical interaction involves concomitant use with Opioids. This combination carries a significant warning due to the risk of profound sedation, respiratory depression, coma, and death. Prescribing together is generally reserved for situations where alternative treatments are inadequate, requiring the lowest effective doses and close monitoring for respiratory issues.

Other CNS depressants and Alcohol can potentiate Castilium's sedative effects. Alcohol, in particular, increases the concentration of Castilium in the bloodstream by approximately 50%, raising the risk of severe CNS depression. Patients are typically cautioned against simultaneous use with any CNS depressant or alcohol.

Metabolic Interactions (Enzyme Effects)

Castilium and its active metabolite are primarily metabolized by CYP2C19. Strong or moderate inhibitors of CYP2C19, such as certain antidepressants or other medicines, can increase the levels of the active metabolite, potentially requiring a dosage adjustment of Castilium. The medicine Cannabidiol (CBD) has also been shown to significantly increase the concentrations of the active metabolite.

Conversely, Castilium acts as a weak inhibitor of the CYP2D6 enzyme. For drugs primarily metabolized by CYP2D6, lower doses may be necessary when co-administered with Castilium to avoid excessive concentrations of the co-administered drug.

Dosage modification is also recommended for patients known to be CYP2C19 Poor Metabolizers due to the inherently higher levels of the active drug component in this population.

Castilium's action is defined by a targeted and selective approach to modulate activity within specific receptor or enzyme systems. It achieves this by engaging defined biological targets and altering key signaling pathways. The drug's influence on core regulatory systems contributes to adjusting the activity level and is used to influence core mechanisms underlying the drug’s effect profile.

Targeting Key Receptor Systems

Castilium's primary action is the high-affinity modulation of the Rxy receptor, a defined biological target within central or peripheral pathways. This interaction directly initiates or blocks specific signaling events, which rapidly adjusts receptor activity and adjusts mediator-driven signaling events in the system.

Modulating Signal Transduction Cascades

Following its initial binding, Castilium operates within well-characterized molecular cascades associated with the Rxy receptor. It modifies early molecular steps, thereby altering the signaling dynamics in defined neural or humoral pathways. This dampens excessive downstream signaling and is applied in contexts involving heightened pathway activation.

Influencing Pathway Regulation

The collective mechanistic effects of Castilium, from receptor binding to cascade modulation, modulate overactive physiological responses. By influencing core mechanisms underlying dysregulation, Castilium contributes to adjusting overactive physiological responses and is used to influence core mechanisms underlying the drug’s effect profile within the targeted biological systems.

Castilium (Clobazam) is used strictly via the oral route, available as tablets, an oral suspension, and a soluble film. Administration is flexible regarding food timing, as the medicine may be taken with or without meals. However, form-specific rules govern intake: the oral film must be placed on the tongue to dissolve without liquid, while tablets may be crushed and mixed with applesauce if swallowing is difficult.

---

Dosing and Frequency

The official protocol requires a low initial daily dose (typically 5 mg or 10 mg), which is often administered in two divided doses (twice daily) when the amount exceeds 5 mg. Doses must be titrated gradually over time, with weekly (7-day) intervals being the minimum period between any adjustment. While the maximum dose for certain regimens is 40 mg daily, certain protocols permit up to 60 mg daily for other approved indications.

---

Population-Specific Adjustments

Specific procedural instructions govern use in sensitive populations. For older adults and patients with hepatic impairment, the recommended starting dose is lower (e.g., 5 mg/day), and they should not exceed half the standard LGS maintenance dose. Furthermore, patients identified as CYP2C19 Poor Metabolizers require the same reduced starting and maximum dosing protocol. The treatment duration varies, with short-term limits applying to certain anxiety uses, while adjunctive epilepsy use is long-term. In all cases, discontinuation must follow a formal, gradual tapering schedule.

Research Evidence / Overview of Studies

Mechanism of Action and Formulation

The research investigated the theoretical activity of the formulation components. Early laboratory work focused on understanding how the compounds interact at the cellular level. Research has explored the distinct pharmacokinetic profiles of the two active components, Compound A and Compound B. Component B, for example, is metabolized into an active compound with a longer half-life, which may contribute to the duration of the combination’s activity.

---

Clinical Efficacy Research

Research has evaluated whether combining Compound A and Compound B examined a potential decrease in the reported intensity and frequency of symptoms. This combination investigated whether it could achieve earlier response rates in participants with chronic conditions.

• Phase II Trials: Initial, short-term trials (duration of 4-8 weeks) focused on establishing the lowest concentration of the combined formulation that showed a measurable effect in laboratory models. These trials primarily assessed pre-defined safety parameters and how well the treatment was received.
• Phase III Trials: Larger, double-blind, placebo-controlled studies lasting up to 12 months were conducted to further examine the long-term response profile. Clinical trials examined the response to this treatment across various participant demographics.

---

Safety and Tolerability Profile

Safety studies primarily focused on monitoring adverse events over the study period.

• Absorption and Metabolism: Pharmacokinetic studies examined absorption rates, including in conditions of fasting. Interactions with high-fat meals were examined in the research.
• Comparative Studies: Studies also compared its profile to existing treatments. This research aimed to provide context on the acceptance of the new combination compared to standard single-agent treatments. The combination’s activity was explored for its effect on overall outcomes.
• Pediatric Studies: Studies involved different administered amounts for pediatric patients under supervision. Studies focused primarily on participants with confirmed Diagnosis Y. These investigations were limited to patients within a specific age range (e.g., 6 to 12 years old) and monitored for treatment response and side effects.

Common questions about Castilium (FAQ)

---

Q: Is it normal to experience mild nausea or headache when first starting Castilium?

Official information states that vomiting is a commonly reported adverse reaction. While headache is generally not listed as a common effect, it has been noted as a possible symptom of hypersensitivity or an allergic reaction in regulatory documents.

---

Q: Does Castilium interact with common over-the-counter medicines like ibuprofen or cold remedies?

Official product information includes a safety caution against using the drug with other central nervous system (CNS) depressants. This class of substances is found in certain non-prescription medicines used for cold, allergy, or sleep issues. The list of ingredients must be reviewed with a prescribing healthcare provider.

---

Q: Are there any vitamins or herbal supplements that should be avoided with Castilium?

The drug has a documented interaction with the prescription drug Cannabidiol (CBD), which is sometimes used as a supplement. Because Castilium is processed by certain body enzymes, its effect may be altered by other supplements that affect these enzymes. Disclosure of all supplements to a healthcare provider is generally recommended.

---

Q: What types of food or drinks can interfere with Castilium?

Alcohol is a substance for which a significant interaction is noted, as it is reported to significantly increase the concentration of the drug in the bloodstream. However, official information states that the drug may generally be taken with or without food.

---

Q: Does having a pre-existing condition like kidney disease or diabetes affect eligibility for Castilium?

Official guidance addresses use in patients with kidney impairment. The regulatory protocol does not specify a dose adjustment for mild to moderate kidney impairment, but data for use in severe renal dysfunction are not available. The official drug label does not specify dosing information related to diabetes.

---

Q: Can Castilium be safely taken with other prescription medications?

Regulatory documents detail that the drug interacts with many prescription medicines. Significant warnings exist regarding co-administration with Opioids and other CNS depressants, which can lead to severe respiratory issues. The use of drugs that affect the body's enzyme systems is documented as potentially requiring a dose change.

---

Q: Is it true that Castilium needs to be taken at a specific time of day to be effective?

Official documentation indicates that doses above a certain daily threshold are typically administered in two divided portions, or twice daily. This approach is intended to help maintain stable blood concentrations of the drug.

---

Q: Is Castilium used in combination with any other drugs for the condition?

According to the official product information, Castilium is indicated for its approved use as an 'adjunctive treatment.' This means the drug is intended to be used in combination with other existing medicines for the condition.

---

Q: What is the common reason people discontinue Castilium?

Regulatory documentation stipulates that discontinuation of the drug should occur at the first indication of potentially life-threatening side effects. Regulatory text highlights the risk of severe dermatological reactions, such as Stevens-Johnson Syndrome (SJS), as a key safety reason for stopping treatment.

---

Q: Are there any lifestyle changes that are recommended while taking Castilium?

Official regulatory warnings include a caution regarding the use of alcohol during treatment. Due to the risk of sedation, a warning exists regarding driving or operating heavy machinery until the drug's effect is known.

---

Q: Is Castilium a brand-name medication or is a generic version available?

The active ingredient, Clobazam, is available under its original brand name and is also marketed by various manufacturers as a generic drug. This generic status is confirmed in the FDA's regulatory filing documents.

---

Q: Is Castilium considered a new type of treatment for its condition?

The active compound, Clobazam, has been in existence for several decades. However, its approval for the specific indication it currently treats was granted by the FDA in 2011.

---

Q: Is there a risk of interaction with birth control pills or hormone therapy?

According to official prescribing information, the drug may reduce the effectiveness of hormonal contraceptives, including birth control pills. A reduction in the effectiveness of these contraceptives is a documented risk, and the need for alternative methods should be discussed.

---

Q: How long does it typically take for Castilium to start working?

Studies on the drug’s processing in the body indicate that the drug itself typically reaches a stable level in the blood within approximately one week. The primary active component it is metabolized into may take up to three weeks to achieve stable concentrations.

---

Q: What happens if I forget to take a dose of Castilium?

The official patient instructions provide a detailed schedule for managing missed doses. This information includes guidance on the appropriate window for taking a dose that was missed and a caution against taking more than the prescribed amount. No specific instruction for missed doses is provided here, as this is individualized advice.

---

Q: Where can I find the official prescribing information for Castilium?

The official, detailed information about the drug is contained in the Full Prescribing Information. This document is published and maintained by regulatory agencies like the U.S. Food and Drug Administration (FDA) on platforms such as DailyMed.

---

Q: Is it necessary to have routine blood tests while taking Castilium?

The regulatory label addresses the potential need for regular monitoring of kidney function for patients on long-term treatment. This is particularly relevant when kidney or liver impairment is present.

---

Q: What if Castilium doesn't seem to be working for the condition it treats?

The official protocol for use includes a gradual dose titration. The gradual increase in dosage, known as titration, is the established mechanism used to find the appropriate dose that achieves the intended effect profile.

---

Q: Is it possible to have an interaction with Castilium even if I take the other substance hours apart?

Studies on the body's processing of the drug indicate that both the medication and its primary active component have long half-lives, meaning they stay in the body for an extended time. Therefore, the potential for interaction with other substances persists for some time after administration.

---

Q: Does the gender of the patient affect the use or side effects of Castilium?

Pharmacokinetic studies examined the processing of the drug in the body and found differences based on gender. Specifically, the volume of drug distribution in the body has been noted to be consistently higher in females than in males.

---

Q: How long after starting Castilium can I expect to see the full effect?

Because the medication is initiated at a low dose and is gradually increased in weekly steps according to the titration schedule, the time required to reach the full effective or maximum dose level may take several weeks.

---

Q: What information is legally required to be provided to patients about Castilium?

The U.S. Food and Drug Administration (FDA) legally requires that patients receive a Medication Guide with each dispensed prescription. This guide contains essential safety warnings, risks, and instructions for proper usage.

How to Store and Dispose of Castilium?

This section outlines the storage, handling, and disposal requirements as mandated by regulatory bodies for the active ingredient, Clobazam.

Storage & Disposal Scope	Official Regulatory Requirements
Temperature Requirements	Store at controlled room temperature (20 C to 25 C). Do not store above 25 C.
Protection and Handling	Keep the medicine from freezing and away from excess heat, moisture, and direct light. Store the oral suspension bottle upright in its outer carton.
Container Requirements	Store Clobazam in the original, tightly closed container it was supplied in.
Stability After Opening	The oral suspension must be used within 90 days of first opening the bottle (US) or 28 days (EU), after which any unused portion must be safely discarded.
Child Safety/Security	The product must be kept out of the sight and reach of children. As a controlled substance, it must be stored in a safe place to protect it from theft.
Disposal Instructions	Unused or expired medication must not be thrown away via wastewater or household waste. Dispose of the product according to local regulations and ask a pharmacist or healthcare provider for guidance.